The EFPIA Pipeline Review has found that in 2020 alone, around 5,000 clinical trials were initiated to investigate and develop new therapies and vaccines. Almost 50% of therapies in development are new substances, with 40% of the pipeline targeting rare diseases, and groundbreaking cell and gene therapies growing in importance. This exciting new wave of medical innovation will play a key role in addressing the challenges faced by patients and healthcare systems. To coincide with the publication of EFPIA’s annual “Pipeline Review”, we are organising a high-level panel discussion around the latest medical research outcomes.